Ambiguity On Diagnostic Regs Has Led To Tough Choices, Says CEO
This article was originally published in The Gray Sheet
Executive Summary
In the current regulatory environment for genetic tests, a manufacturer's best business plan may dictate an opposite path to market than its concerns about patient safety, says Tm Bioscience CEO Greg Hines